Remus Pharmaceuticals Ltd. (REMUS-SM) Share Price Rises 8.06% as Small Cap Stock Enters Top Gainers Today

Remus Pharmaceuticals Ltd. Share Price moved higher on 20 August 2026, with the stock trading at Rs 949.8, up Rs 70.85 or 8.06% for the day. With a market capitalisation of Rs 1,053.25 crore, the company stood out in Stock Market Today as a small-cap name that cleared the workflow’s price rise event bar for its market-cap category. The move is significant because it was not just a marginal uptick in the share price; it was a sizeable same-day gain backed by visible trading activity on the NSE.

From the supplied data, the stock opened at Rs 883, traded between Rs 879 and Rs 967.05, and remained well above the previous close of Rs 878.95 through the session snapshot used for this article. That intraday range suggests sustained interest rather than a brief isolated print. Turnover came in at Rs 4.5 crore, while traded volume was 47,400 shares on the NSE, keeping Remus Pharmaceuticals Ltd. Stock News in focus among market movers and top gainers today.

The available data confirms the price event, but it does not establish a company-specific catalyst for why the stock is rising today. Even so, the numbers offer enough for meaningful stock analysis. Investors tracking Remus Pharmaceuticals Ltd. Share Price Today can examine how the price action, valuation, profitability and peer positioning fit together. In this Univest review, the emphasis stays on verified data: what happened, how the stock is valued, how it compares with the Trading industry benchmark, and what metrics deserve the closest watch next.

Remus Pharmaceuticals Ltd. (REMUS-SM) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 949.8
Previous Close	Rs 878.95
Today's Change	+Rs 70.85 (+8.06%)
Day Open	Rs 883
Day High	Rs 967.05
Day Low	Rs 879
Current Volume (NSE)	47,400
NSE Traded Volume	47,400
Combined NSE + BSE Volume	47,400
Turnover	Rs 4.5 crore
Market Capitalisation	Rs 1,053.25 crore
Market Cap Category	Small Cap

Remus Pharmaceuticals Ltd. (REMUS-SM) traded at Rs 949.8. versus the previous close of Rs 878.95, a rise of 8.06%. The stock opened at Rs 883, reached Rs 967.05, touched Rs 879. Reported volume was 47,400.

Remus Pharmaceuticals Ltd. (REMUS-SM) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 1,053.25 crore
P/E Ratio	28x
P/B Ratio	2.95x
ROE	40.49%
ROCE	48.84%
EPS	Rs 31.39
Dividend Yield	0.11%

Remus Pharmaceuticals Ltd. was valued at a P/E ratio of 28x, a P/B ratio of 2.95x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 40.49% and ROCE of 48.84%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 31.39, dividend yield of 0.11%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Remus Pharmaceuticals Ltd. Fundamental Analysis shows a company that is not only drawing interest because of price action but also carries notable profitability metrics. At the current market cap of Rs 1,053.25 crore, the stock trades at a P/E ratio of 28 and a P/B ratio of 2.95, placing valuation in a range that can be compared directly with its industry benchmarks and listed peers.

On profitability, the supplied numbers are strong. Return on equity stands at 40.49%, while return on capital employed is 48.84%. Those are high figures in absolute terms and suggest the business has been generating meaningful returns on shareholder equity and capital employed. For investors reading Remus Pharmaceuticals Ltd. Financial Results through a valuation lens, those returns are important because they help explain why the market may assign a multiple above some lower-return peers.

EPS is Rs 31.39, which indicates the earnings attributable to each share based on the supplied data. When compared with the current share price of Rs 949.8, that supports the stated P/E ratio of 28. The dividend yield is 0.11, a relatively small historical payout relative to the current stock price, which implies the current investment case in the data is more closely tied to earnings power and market valuation than to income distribution.

From a financial analysis perspective, the combination of a 28 P/E, 2.95 P/B, 40.49% ROE and 48.84% ROCE gives Remus Pharmaceuticals Ltd. Share Price a more substantial fundamental context than a price move alone would suggest. It does not prove a fresh catalyst, and Univest is not inferring one from absent disclosures. But it does show that today’s market attention is landing on a company with strong profitability ratios already visible in the supplied figures.

That makes the next layer of analysis especially relevant: whether the Trading industry benchmark and peer set support the view that the stock is expensive, inexpensive or broadly aligned relative to the numbers available.

Sector and Industry Context

Metric	Value
Sector	Trading
Industry	Trading
Benchmark Scope	same industry
Company P/E Ratio	28x
Benchmark Median P/E	22.02x
Benchmark Average P/E	109.78x
Benchmark P/E Range	0.11x to 7,785.96x
Company P/B Ratio	2.95x
Benchmark Median P/B	1.3x
Company ROE	40.49%
Benchmark Median ROE	2.08%
Company ROCE	48.84%
Benchmark Median ROCE	4.5%
Company Market Capitalisation	Rs 1,053.25 crore
Benchmark Median Market Cap	Rs 46.38 crore

Remus Pharmaceuticals Ltd. (REMUS-SM) is classified under sector: Trading and industry: Trading.

Remus Pharmaceuticals Ltd. (REMUS-SM) has a P/E ratio of 28x, which is above the benchmark median of 22.02x, a difference of +27.16%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Remus Pharmaceuticals Ltd. (REMUS-SM) has a ROE of 40.49%, which is above the benchmark median of 2.08%, a difference of +1,846.63%. Remus Pharmaceuticals Ltd. (REMUS-SM) has a ROCE of 48.84%, which is above the benchmark median of 4.5%, a difference of +985.33%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

The sector data places the company inside the Trading industry, and that benchmark helps frame whether today’s interest is only about price action or also about relative fundamentals. Against a same-industry universe of 439 companies, Remus Pharmaceuticals Ltd. shows stronger profitability than the median and average benchmark figures supplied.

The benchmark scope is explicitly the same industry, covering 439 companies. Within that group, the company P/E of 28 compares with a median P/E of 22.02 across 323 companies and an average P/E of 109.78, with a range running from 0.11 to 7,785.96. That places Remus Pharmaceuticals Ltd. Share Price on a valuation multiple above the industry median but far below the industry average, showing how broad the valuation spread is inside the Trading segment.

On book value multiples, the company P/B of 2.95 compares with a median of 1.3 across 438 companies and an average of 0.62, while the benchmark range extends from -1,160.8 to 383.33. This means the stock is trading above both the median and average P/B figures in the same-industry set. In isolation that suggests a richer valuation than a typical Trading company, but valuation needs to be read alongside profitability.

That is where the sector comparison becomes more striking. The company ROE of 40.49% is far above the industry median of 2.08% and the average of 8.19% across 436 companies. Its ROCE of 48.84% is also well above the median of 4.5% and average of 4.61% across 436 companies. Market capitalisation is Rs 1,053.25 crore versus an industry median of Rs 46.38 crore and an average of Rs 21,330.78 crore, with the range spanning Rs 1.11 crore to Rs 92,75,252.6 crore. For Univest, that sector picture suggests a company larger than the median peer and materially stronger than the benchmark on return ratios, even as the share price trades at a premium to median valuation levels.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Diksha Greens Ltd.	DGL	92,75,252.6	0	0	-25.83	-6.36
Elitecon International Ltd.	ELITECON	2,727.04	8.7	5.99	-1.29	-1.22
Fischer Medical Ventures Ltd.	FISCHER	2,665.49	91.08	5.83	0	-11.19
SIRCA Paints India Ltd.	SIRCA	2,514.79	37.47	5.11	12.99	17.3
Confidence Petroleum India Ltd.	CONFIPET	2,330.67	17.9	1.63	9.89	12.79

Remus Pharmaceuticals Ltd. (REMUS-SM) has a P/E ratio of 28x compared with the displayed peer median of 17.9x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 40.49% compares with a peer median of 0% across the companies shown in the table. ROCE stood at 48.84% versus the displayed peer median of -1.22%, providing a capital-efficiency comparison. Remus Pharmaceuticals Ltd. (REMUS-SM) has a market capitalisation of Rs 1,053.25 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

The peer snapshot shows Remus Pharmaceuticals Ltd. in a mixed but interesting position. Its valuation is neither the cheapest nor the most expensive in the listed comparison set, while its profitability ratios stand out positively against many peers. That combination helps explain why the stock can attract attention during today’s rally without relying on an identified corporate trigger.

Among the supplied peers, Elitecon International trades at a P/E of 8.7 and P/B of 5.99 with ROE of -1.29% and ROCE of -1.22%, while Fischer Medical Ventures trades at a P/E of 91.08 and P/B of 5.83 with ROE of 0% and ROCE of -11.19%. SIRCA Paints India shows a P/E of 37.47, P/B of 5.11, ROE of 12.99% and ROCE of 17.3%. Confidence Petroleum India trades at 17.9 times earnings and 1.63 times book with ROE of 9.89% and ROCE of 12.79%. Vintage Coffee & Beverages stands at a P/E of 28.47 and P/B of 3.9 with ROE of 3.02% and ROCE of 4.38%.

Against those numbers, Remus Pharmaceuticals Ltd. Share Price appears roughly aligned with Vintage Coffee on earnings multiple, above Confidence Petroleum and Elitecon, but below Fischer Medical Ventures and SIRCA Paints. On P/B, the company’s 2.95 is lower than Elitecon, Fischer, SIRCA, Vintage and Khazanchi Jewellers at 5.73, but above Confidence Petroleum at 1.63 and Hindware Home Innovation at 2.24.

The biggest relative strength is profitability. Remus Pharmaceuticals reports ROE of 40.49% and ROCE of 48.84%, both comfortably above Elitecon, Fischer, SIRCA, Confidence Petroleum, Vintage Coffee, Khazanchi Jewellers at 12.06% ROE and 7.94% ROCE, Aayush Art And Bullion at -5.74% ROE and -5.54% ROCE, and Creative Newtech at 18.77% ROE and 19.11% ROCE. Hindware Home Innovation is one of the few peers near the company on returns, with ROE of 47.53% and ROCE of 44.69%.

In market-cap terms, Remus Pharmaceuticals at Rs 1,053.25 crore is smaller than the listed peers shown from Rs 1,660.38 crore upward, while Diksha Greens is an extreme outlier at Rs 92,75,252.6 crore despite negative ROE of -25.83% and ROCE of -6.36%. Univest reads this peer set as evidence that the stock’s valuation is not detached from its profitability profile, though it is not a low-multiple name either.

Why Investors Are Watching Remus Pharmaceuticals Ltd.

Today’s move has put the stock on the radar because the price action, profitability profile and peer context all offer something concrete to analyse. While the supplied data does not identify a company-specific reason, Remus Pharmaceuticals Ltd. Share Price has become relevant in Stocks in News because the gain was strong enough to qualify within its small-cap category and because the underlying ratios are notable.

• Verified price action: the stock rose Rs 70.85, or 8.06%, to Rs 949.8 from Rs 878.95.
• Intraday strength: it opened at Rs 883, touched Rs 967.05 and held far above the day low of Rs 879.
• Volume backdrop: 47,400 shares changed hands on the NSE with turnover of Rs 4.5 crore.
• Fundamental context: P/E is 28, P/B is 2.95, ROE is 40.49%, ROCE is 48.84%, EPS is Rs 31.39 and dividend yield is 0.11.
• Sector positioning: ROE and ROCE are well above same-industry medians and averages.

What investors may monitor next is whether the stock continues to hold closer to the upper end of today’s range, how the current valuation compares with future financial updates, and whether the strong return ratios remain a distinguishing feature versus peers. Univest also notes that

About Remus Pharmaceuticals Ltd.

Based on the supplied classification, Remus Pharmaceuticals Ltd. operates within the Trading sector and the Trading industry. That means the clearest verified company context available for Remus Pharmaceuticals Ltd. Share Price is its position inside this listed industry basket rather than a longer business profile or segment disclosure.

Even with limited descriptive fields, the market data offers useful context. The company has a market capitalisation of Rs 1,053.25 crore, which places it well above the industry median market cap of Rs 46.38 crore but below several larger listed peers in the comparison set such as Elitecon International, Fischer Medical Ventures, SIRCA Paints India, Confidence Petroleum India, Vintage Coffee & Beverages, Khazanchi Jewellers, Aayush Art And Bullion, Creative Newtech and Hindware Home Innovation.

Its financial profile within this industry is notable for strong return metrics. A ROE of 40.49% and ROCE of 48.84% stand far ahead of the industry median and average supplied for the Trading benchmark. That helps distinguish the company from many peers that either generate lower returns or, in some cases, show negative return ratios. The stock’s P/E of 28 and P/B of 2.95 indicate that the market is not valuing it like a distressed or deeply discounted name, but rather assigning a valuation that sits above benchmark medians while remaining far below the most expensive extremes in the broader industry range. For readers following Remus Pharmaceuticals Ltd. Latest News, that combination of price action and relative profitability is the key verified company context available today.

Track Remus Pharmaceuticals Ltd. Share Price on Univest

Use Remus Pharmaceuticals Ltd. (REMUS-SM) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors tracking Remus Pharmaceuticals Ltd. Share Price can use Univest to follow live share price moves, day change, market capitalisation and 52-week market context when available. Univest also helps users monitor valuation ratios such as P/E and P/B, profitability indicators including ROE and ROCE, and stock analysis metrics that shape day-to-day market interpretation.

For users interested in Remus Pharmaceuticals Ltd. Share Price Today, Univest brings together price updates, market insights, peer context, shareholding pattern data when reported, and broader sector comparisons in one place. That makes it easier to track whether a stock is moving mainly on price action, on changing fundamentals, or within a wider trend across the Indian stock market. For this stock, today’s rise is the headline, but the supporting ratios are just as relevant.

Frequently Asked Questions

Why is Remus Pharmaceuticals Ltd. Share Price in focus today?

Ans. Remus Pharmaceuticals Ltd. Share Price is in focus because the stock rose 8.06% in a single session to Rs 949.8, gaining Rs 70.85 over the previous close of Rs 878.95 and entering the small-cap top gainer conversation.

What was the latest Remus Pharmaceuticals Ltd. Share Price Today?

Ans. The latest supplied Remus Pharmaceuticals Ltd. Share Price Today was Rs 949.8. At that level, the stock was up 8.06% for the day, after opening at Rs 883 and trading within an intraday range of Rs 879 to Rs 967.05.

How much did Remus Pharmaceuticals Ltd. rise today?

Ans. The stock rose Rs 70.85 on the day, which translated into an 8.06% gain. That move came from a previous close of Rs 878.95 to a current price of Rs 949.8 in the supplied market snapshot.

What does today’s intraday range show for the stock?

Ans. The intraday range ran from Rs 879 to Rs 967.05 after an opening price of Rs 883. This shows the stock moved sharply higher during the session and was still trading closer to the day’s high than the low.

What is the market capitalisation of Remus Pharmaceuticals Ltd.?

Ans. Remus Pharmaceuticals Ltd. had a market capitalisation of Rs 1,053.25 crore in the supplied data. That places it in the Small Cap category and well above the Trading industry median market cap of Rs 46.38 crore.

Is Remus Pharmaceuticals Ltd. expensive compared with its industry P/E benchmark?

Ans. The company trades at a P/E of 28, above the same-industry median of 22.02 but far below the average of 109.78. That suggests valuation is richer than the median benchmark, though not extreme within the wider industry range.

How does the company compare on profitability ratios?

Ans. Profitability looks strong in the supplied figures. ROE stands at 40.49% and ROCE at 48.84%, both materially above the industry median values of 2.08% and 4.5%, as well as the average benchmark levels.

What are the key fundamental metrics investors are tracking?

Ans. Key supplied fundamentals include a P/E of 28, P/B of 2.95, EPS of Rs 31.39, ROE of 40.49%, ROCE of 48.84% and dividend yield of 0.11, giving investors valuation and profitability context for today’s move.

How active was trading in Remus Pharmaceuticals Ltd. on NSE today?

Ans. Trading activity was 47,400 shares on the NSE, which also represented total reported volume in the supplied snapshot. Turnover stood at Rs 4.5 crore, giving the day’s price rise a measurable participation backdrop.

Has the supplied data identified a company-specific catalyst for the rise?

Ans. The supplied data confirms the price rise event but does not establish a company-specific catalyst. What is visible instead is a strong one-day gain, active NSE turnover, and profitability metrics that compare well with industry benchmarks.